Genetic counselors are trying once again to gain Medicare recognition through this bill, so they can bill for their services.

Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how ...

Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...

CS-101 is Shanghai-based CorrectSequence's lead candidate, which it is developing for treating sickle-cell disease and ...

The companies will leverage Bayer's expertise in developing medicines for heart conditions and Soufflé's siRNA delivery technologies to advance the treatment.

NEW YORK – ALX Oncology said on Thursday that it has treated the first patient in a Phase II trial evaluating its CD47-inhibitor evorpacept in HER2-positive breast cancer. The firm additionally ...

NEW YORK – A2 Biotherapeutics announced on Wednesday that the US Food and Drug Administration cleared its investigational new drug application to begin a trial of its autologous IL-12-boosted CAR ...

NEW YORK – Sarepta Therapeutics on Wednesday said it submitted an application to regulators in New Zealand, seeking to begin a first-in-human trial of SRP-1005, the siRNA drug it's developing for ...

So far, the BCMA-targeted CAR has shown early success in four Australian multiple myeloma patients in a Phase I trial.

In the Phase III results, Ziihera plus immunotherapy and chemo improved survival outcomes compared to Herceptin plus chemo.

With this new grant, nonprofit A Race Against Blindness has provided a total of $5.1 million to advance AXV-101.